SUCCESS

T-Mobile has lost a major ranking amid increased competition in the telecommunications market. 

Over the past year, T-Mobile has struggled with customer retention as AT&T and Verizon have ramped up promotions, discounts, and, more recently, lower-priced phone plans to lure price-conscious consumers. 

Cable operators have also become a growing threat as they roll out bundled phone, internet and cable TV deals to attract customers. For instance, in the first quarter of 2026, Spectrum added 406,000 new wireless lines, while Comcast gained 448,000, according to their latest earnings reports.  

Against this backdrop, and amid recent phone plan changes and price increases, T-Mobile Chief Financial Officer Peter Osvaldik said on an earnings call in July that the company expects its postpaid phone churn (the percentage of postpaid phone customers who ended their service) to be temporarily “elevated.”

T-Mobile suffers stock downgrade amid rising competition

As T-Mobile faces competitive headwinds, Wolfe Research has downgraded its outlook for the carrier’s stock performance, according to an analyst note unveiled in a recent Investing.com report. 

Wolfe Research lowered the stock’s rating from outperform, which indicates a stock will perform slightly better than the overall market, to peer perform, which suggests it will perform at the same level as other businesses in its industry. 

In the analyst note, Wolfe Research analyst Peter Supino expects T-Mobile’s revenue growth to be negatively impacted by mounting competitive pressures and recent investments, which will likely result in spending exceeding the $20 billion in flexible capacity mentioned in its long-term guidance. 

“Long-term revenue growth forecast risk tilts negatively as competition expands in T-Mo’s core,” said Supino. “Broadband and 6G investments could dampen capital returns and pressure leverage.”

Related: T-Mobile customers face new restriction when paying bills 

The firm expects T-Mobile to face sluggish ARPU (average revenue per user) growth after it discontinued several legacy wireless plans that launched almost 15 years ago. This change resulted in customers on these plans being automatically moved to higher-priced ones. 

Wolfe Research also predicts that Verizon and AT&T will grow rapidly and could even potentially match T-Mobile’s performance within the next four years, another reason for the downgrade in rating.

Supino also raised red flags around T-Mobile’s recent leadership departures. For example, after 21 years with the company, Callie Field stepped down as president of T-Mobile’s business group in September last year. 

More recently, Mike Katz left his position as T-Mobile’s chief business and product officer in July after 28 years and will serve as a strategic advisor at the company through December. 

Additionally, Supino raised concerns about reports that T-Mobile may merge with its parent company, Deutsche Telekom. However, this deal has allegedly been stalled due to worries from the carrier’s U.S. executives about potential regulatory issues, according to an Investing.com report in July. 

Supino said that the recent departures and potential merger spark questions about T-Mobile’s alignment of interests. 

Wolfe Research downgrades T-Mobile’s stock from outperform to peer perform amid competitive pressures. Bloomberg / Getty Images

T-Mobile faces a looming threat from SpaceX’s Starlink Mobile 

Concerns over T-Mobile’s ability to weather intensifying competition come at a time when SpaceX’s Starlink Mobile, which the carrier currently partners with to offer T-Satellite direct-to-cell service, is planning to build its own terrestrial network. 

This will be powered by its satellites and smaller terrestrial ground stations, which it plans to build. 

SpaceX Chief Operating Officer Gwynne Shotwell said during an earnings call on Aug. 4 that the company will begin launching its next-generation Starlink Mobile V2 satellites in 2027. 

These new satellites are built to provide 5G speeds from space, with 100 times the data density of Starlink’s first-generation V1 satellites. That added capacity means each satellite can handle up to 20 times more traffic. 

More T-Mobile News:

T-Mobile customers face new restriction when paying bills 

T-Mobile excludes 2 generous customer perks from new phone plans

T-Mobile faces backlash over new customer support restriction

For Starlink Mobile customers, that will translate into faster and more dependable service for browsing the internet, running data-heavy apps, streaming and making calls, with fewer service disruptions.

Shotwell said she believes Starlink Mobile could draw customers away from T-Mobile, AT&T, and Verizon with its upcoming terrestrial network.

“I anticipate us to be able to acquire quite a few of their customers because I think our service will be better,” she said. “We will eliminate dead zones leveraging basically the satellites in orbit.”

In an analyst note in July, TD Cowen analyst Gregory Williams warned that if SpaceX plans to offer terrestrial mobile service, it could significantly disrupt the wireless industry, especially if it doesn’t reach an MVNO (mobile virtual network operator) agreement with T-Mobile, AT&T or Verizon, according to a MarketWatch report. 

“Any entry of SpaceX could be highly bearish for the wireless industry,” said Williams. “As such, we are hopeful but not convinced that no carrier will budge and cave on an MVNO agreement.”

Related: T-Mobile excludes 2 generous customer perks from new phone plans

TheStreet aims to feature only the best products and services. If you buy something via one of our links, we may earn a commission.

Why we love this deal

It seems like summer just arrived, and yet already kids are packing up and heading back to school. For college folks, that includes a whole host of items in addition to the standard school supplies you pick up every August. Compact fridges, under-bed storage, and portable bathroom products to take on your trips to the hall showers, like the Dakimoe Shower Caddy, are all at the top of the list when it comes time to prepare for the back-to-school season, and making sure you invest in the right one and save money when you can is at the top of our back-to-school list.

The Dakimoe Shower Caddy is one of our favorite affordable products, already well-priced at just $25 at Walmart, but now, thanks to a Flash deal, it’s just $14 for a limited time. Save $11 and get the organization mesh bag perfect for keeping your products tidy and, most importantly, free of mildew and mold.. 

Dakimoe Shower Caddy, $14 (was $25) at Walmart

Courtesy of Walmart

Shop at Walmart

Why do shoppers love it?

Shower caddies like the ones students use in college dorms and apartments typically are made of mesh or plastic, and both materials have their merits. Plastic is easier to clean and more likely to collect mildew or mold from soap and water buildup if you’re not careful, but it’s often harder to neatly pack items together, with no room for pockets or slots for organization. Mesh, as long as you properly drain excess water and keep it clean, usually has more room for shampoos, conditioners, and soap, while also allowing you to better organize it with pockets and slots. 

The caddy, which measures 19.4 inches long, 5.9 inches wide, and 10.4 inches high, has a square cube shape and is made with waterproof Oxford fabric and mesh. It’s engineered with a quick-dry construction to ensure that wet items are separated properly, preventing mildew and unpleasant odors, while also being flexible and more pliable to fit large or oddly-shaped bottles and fold completely when it’s not in use.

With a large hook for easy hanging in the shower or on the back of your door, this all-in-one caddy is super roomy, with seven interior flexible slots and pockets for things like toothpaste, a toothbrush, a hairbrush, and other smaller or thinner items. You can also choose to forgo using the slots and fit up to four full-sized bottles of shampoo, conditioner, body wash, and lotion. The top of the caddy has an additional pocket, and the exterior has two mesh side pockets as well. There’s even a waterproof, clear front pouch for your smartphone. It protects your device while still allowing you to use its touchscreen abilities.  

Related: College dorm room storage and organization is up to 53% off at Walmart

This multi-pocket, multi-functional caddy is ideal for dorm life but just as usable for those still at home who need some organizational help. It’s also great for travel. Pack it in your suitcase and use it to keep all of your toiletries in one place while staying in hotels to prevent accidentally leaving something behind. 

Details to know

Material: Waterproof Oxford fabric

Dimensions: The bag measures 10.4 inches long, 5.9 inches wide, and 10.4 inches high.

Colors: Two. 

Features: The foldable bag has seven interior pockets, a lid interior pocket, exterior mesh side pockets, a large hanging hook, and a waterproof, front clear pouch for your smartphone.

Perfect for everything from the dorm shower to a weekend getaway to a daily trip to the pool, this shower caddy offers a lot of space to fit all your bath and shower products. A big hit with college kids who have community bathrooms, it is very sturdy, dries out well, and it’s super handy for keeping hair products, body wash, and small accessories nice and organized. 

Shop more deals 

Virtu Back-to-College Dorm Room Essentials Bedding Set, $57 (was $100) at Walmart

Dakimoe School Backpack, $27 (was $37) at Walmart

Keurig K-Express Essential Single-Serve K-Cup Coffee Maker, $49 (was $55) at Walmart

Keep your products organized and easily accessible, whether you live in a dorm or are headed away for the weekend, with the Dakimoe Shower Caddy.

Treasury Secretary Scott Bessent’s plan to calm markets is being short-circuited.

Key Takeaways

Pet insurance policies usually work by reimbursement: you pay first and insurance pays you back later.
Most claims require itemized invoices and medical records from the veterinarian who treated your pet
From the time you submit your claim to when you receive reimbursement, the process can take between two and 30 days.

Pet insurance can help offset unexpected vet bills. In a new study by Money.com and Healthy Paws Pet Insurance, three in four policyholders said their plan significantly reduced their out-of-pocket expenses. A follow-up survey also found that insured owners were nearly 50% more likely to approve all recommended treatments regardless of cost.
But that money doesn’t arrive right away. Because most plans reimburse after treatment, you’ll typically need to pay upfront and submit a claim to get your money back later.
Filing a claim is generally a simple process: you fill out a form online or through an app, attach a receipt and your pet’s medical records, and wait. If everything checks out, the money could land in your account within a few days.
Even so, there are a few common missteps that can derail your claim. Here’s a step-by-step guide to keep things running smoothly.

How do pet insurance claims work?
Unlike human health insurance, most pet insurance plans require you to pay the full cost of your dog or cat’s treatment first and then submit a claim to your insurer. If the claim goes through without any hiccups, the reimbursement turnaround is usually quick — most people get a direct deposit or a check in the mail within a few days.
How to file a pet insurance claim
1. Take your pet to a licensed veterinarian
The first (and most critical) step is to visit a licensed veterinarian. You can visit any licensed vet at an emergency clinic or animal hospital in the United States (and sometimes Canada). However, if your pet insurance company allows direct payments to vets, and you want to use this benefit, your options are limited to pre-authorized vets or hospitals.
2. Be prepared to pay 100% of the bill first
When you go to a regular doctor, you usually pay your share of the cost, and the doctor settles the rest of the bill with the insurance company. Pet insurance works differently. After paying the bill, you — not the vet — handle the claims process with the insurance company.
3. Have a look at your policy’s fine print
Generally, companies accept claims within 90 to 180 days of the treatment date, so be sure to submit your reimbursement request during your policy’s claims window. Another detail to remember is that pet insurance won’t accept a claim if you haven’t settled the bill at the vet; the invoice must show a balance of $0 or “paid in full.”
4. Round up the necessary documents and submit your claim
Having the following paperwork ready can minimize unnecessary back-and-forth:

Your veterinarian’s contact info
An itemized invoice
Proof of payment (like a receipt)
The veterinary diagnosis
Test results, like bloodwork or X-rays

If this is your first claim with that company, the representative handling your case may also request your pet’s full medical records.
Once you have everything, you can fill out the claim form online or on your phone. You will be asked to explain the incident, your pet’s treatment and to provide supporting documents and medical records. This part typically takes just a few minutes.
5. Stay tuned for any follow-up questions
After you submit your claim, keep an eye on your notifications. It can take anywhere from two to 30 days for an insurer to process a claim, and the person who is handling your claim may reach out with questions during this time.
6. Hang tight for the refund
If the insurer approves your claim, the direct deposit or check should be on its way within a few days. How much money you get depends on the policy’s deductible, reimbursement rate and annual coverage limit.
Let’s say your insurance plan has an 80% reimbursement rate, a $10,000 annual coverage cap and a $250 deductible. If you submit your first claim for a $1,000 ER trip after your dog ate one too many chicken bones, and the claim is approved, insurance would reimburse you $600.
If your pet insurance claim is denied, you still have options. The first step is to file an appeal with the insurance company within 14 to 30 days from the date you get the denial letter (the actual appeal window varies by insurer). Next, submit new documentation that supports your case, and wait for the company’s response. Once you’ve exhausted the insurer’s appeal process, you can escalate the issue with your state insurance regulator if you still believe the denial is wrong.

FAQ
How long do pet insurance claims take?
Claims can take anywhere from two to 30 business days to process. If your claim is denied and you file an appeal, the revision process can take an extra month or so.
What are common reasons for claim denials?
Pet insurance companies typically deny claims for pre-existing conditions or illnesses that came up during the policy waiting period. Insurers can also deny claims if you’re missing a document or if you reached the policy’s coverage limit.
Does pet insurance go up if you claim on it?
No, pet insurers typically won’t increase your premium just because you filed a claim. That said, you may still see annual rate increases of 10% to 30% as insurers reassess factors such as your pet’s age, rising veterinary costs and breed-specific claims data.

More from Money
More Pet Owners Are Going Into Debt to Pay Vet Bills. Here’s Why That’s Risky
The Lifetime Cost of a Pet — and How to Pay for It
How Much Does It Take for Pet Owners to Hit Their Financial Limit?

For highly ambitious entrepreneurs and digital nomads, Bali has transformed from a mere holiday destination into a strategic addition to a global investment portfolio. However, making a smart real estate play on the island requires looking past the stunning aesthetics and understanding the hard mechanics of the local market.
When you start browsing property, the phrase “sea view” covers two entirely different realities—and the gap between them costs serious money. Of the villas listed with a view of the water, only about two-thirds are actually described as being by the sea. This means a full third of them look at the ocean from a vast distance that involves a car, a steep lane, or both.
Anyone comparing villas for sale in Bali with sea view needs to establish early which of the two a listing is actually selling.
To maximize your ROI and avoid amateur mistakes, here is how you must analyze the three distinct regions of the island and the legal realities of foreign ownership.
Location Strategy: How Bali Prices the Ocean
Across the island, there are currently 114 villas in the sea view category, priced anywhere from roughly $150,000 for a 40 m² one-bedroom house on the east coast, up to about $2.44 million for a 515 m² four-bedroom near Denpasar. This pricing maps almost exactly onto three specific parts of the island.

The Bukit: Selling Height, Not Access
The limestone peninsula in the south—covering Ungasan, Pecatu, and South Kuta—is where Bali’s famous cliff views come from. Villas here sit 50 to 100 metres above the water with an uninterrupted horizon, which is precisely why the view commands a premium. A one-bedroom of 75 m² in Ungasan runs near $315,000, while a 108 m² house in South Kuta sits around $265,000.

The catch: Distance to the sea here is often measured in kilometres rather than metres; 1.1 km down a steep cliff road is not a useful walk to the beach. Badung province holds 326 villa listings—the deepest pool on the island—and much of the newer construction is concentrated here.
The West Coast: Trading Views for Action
Kerobokan, Canggu, and the strip running north are the busiest parts of the island’s property market. The land is flat and the buildings are low, meaning a sea view survives only if a plot directly faces the beach or backs onto open rice fields. What buyers are actually purchasing here is pure location: restaurants, coworking spaces, schools, and a highly lucrative rental market that runs all year long. Prices reflect this demand: a two-bedroom in Kerobokan sits near $490,000, while a six-bedroom can reach close to $698,000. The honest way to read the west coast is that the ocean is a bonus there, not the main product.
The East Coast (Karangasem): The Value Corner
If you want water at your doorstep without paying the Canggu premium, the eastern regency around Amed and Candidasa is the island’s value corner. Villas here sit within metres of the water—with listings recording distances as close as 10 m to the sea. Prices are drastically lower: a one-bedroom comes in near $150,000, and a two-bedroom sits around $487,500.

The trade-off: Karangasem holds only 13 villa listings compared to Badung’s 326, the drive from the airport takes two hours or more, and the rental season is much shorter and quieter. For anyone relying on year-round short lets to build cash flow, this thin market is a genuine constraint.

Asset Protection: What Foreign Buyers Actually Own
For entrepreneurs, the ownership question matters far more than the view. The structures available to foreigners differ sharply in what they actually secure, and making a mistake here can cost you your entire investment.

Freehold (Hak Milik): Strictly reserved for Indonesian citizens. It is not available to foreign buyers under any structure, regardless of what a shady listing might imply.
Leasehold: The most common route, typically lasting 25 to 30 years. Since renewal is negotiated in the contract rather than guaranteed by law, the renewal clause is the single most important paragraph in your agreement.
Hak Guna Bangunan (Right to Build): Runs for 30 years with extensions that can reach 80 years in total. It is usually held through a PT PMA, an Indonesian company with foreign ownership. Since a PT PMA carries minimum capital and reporting obligations, it perfectly suits an investment held as an actual business rather than just a holiday house.
Hak Pakai (Right to Use): Runs up to 25 years with a 20-year extension, but is tied to your residency status (requiring a KITAS or KITAP permit).
Nominee Arrangements: Having an Indonesian citizen hold freehold on your behalf remains legally unenforceable. This arrangement is the core reason behind almost every cautionary horror story about foreigners losing their money on the island.

Evaluating Listings & The Smart Money Sequence
Comparing the three regions side by side is easier when the listings state distance to the water alongside price and area. The Bali villa catalogue on Global-Property.Investments breaks the island down by regency and by view, so a shortlist can separate cliff-top panoramas from genuine beachfront before anyone books a flight.
The practical order of decisions runs backwards from the usual one. Settle the ownership structure first, since it determines the term, the exit, and the tax treatment. Then choose the coast, because the Bukit, the west, and the east are three markets with different prices, climates, and rental patterns. The view comes last, and only after someone has stood on the terrace and worked out how long it takes to reach the sand. On Bali, that walk is where the difference between a view and a location shows up.
The post The Entrepreneur’s Guide to Investing in Bali Real Estate Without Getting Burned appeared first on Addicted 2 Success.

I have sat with founders who built something that actually works. Customers who buy, stay. The product is not the problem. The week is.
Sales is still what keeps the lights on, and a lot of smart people treat it like a mood. They hustle when they feel brave, go quiet when a few calls go badly, then wonder why the calendar looks empty again. You can work long hours and still leave money sitting there if you never get clean on how a lead becomes a conversation, how a conversation becomes a presentation, and how a presentation becomes a yes.
None of this is magic. It is a handful of habits most people skip because they feel slightly awkward. They also happen to be the ones that keep a pipeline from drying up.
1. Pitch the insight before you pitch the fix
The calls that die usually start with the product. Features, screens, a little origin story, then a price. The calls that limp along start with a method and then slide into the offer. The ones that close start somewhere else.
They start with an insight. A way of seeing the prospect’s world that they have not said out loud yet. It is not about you. It is not a humblebrag. It is you proving you understand the mess they are in better than the last three people who tried to sell them something.
A trainer who gets results does not open with a workout plan. They talk about why the weight will not move even when the person is “doing everything right.” Sleep. Stress. The plateau nobody warned them about. Once that lands, the program is the obvious next step, not a pitch.
Before your next call, write down five to ten of those. Steal them from deals you have already lived through. When the conversation turns a certain way, pull the one that fits. Only after their view of the problem has shifted do you bring your offer in as the logical move.
If your “insight” is a recycled industry stat they have already seen in a LinkedIn post, skip it. They can smell that.
2. Stop guessing why a pitch lived or died
Most founders grade a call by feeling. That one felt warm. That one felt off. Then they change nothing, or they change everything, which is almost the same thing.
Record the presentations. Get them written down. Then sit with the ones that closed next to the ones that went nowhere.
You will hear things you missed in the moment. How long you talked before they said anything useful. The question that opened the room. The joke that killed the energy. The point where you got defensive and started explaining instead of asking.
If you want a faster read, drop the transcripts into an AI tool and ask it to compare the two piles. Look for themes, not a new personality. The goal is not a script that makes you sound like someone else. The goal is to stop repeating the same miss because you never actually listened to yourself.
You cannot fix what you refuse to look at.
3. When they object, stop playing tennis
Price comes up and the amateur hits it back. Timing comes up and they hit that back too. It turns into a match, and nobody likes being in a match with someone who is trying to take their money.
Catch the ball. Hold it.
They say they are not sure about the price.
You say, “Okay. Price matters. Let me write that down. What else is sitting with you?”
Then you wait.
Collect all of it. Price, timing, a feature they do not trust, a partner they have to run it by. Keep going until they tell you that is the full list. Then you answer the pile as one conversation.
The first objection is often a test. If you pounce on it, they never give you the real one. When you write it down and ask what else there is, they usually exhale. They feel heard instead of handled. You also stop burning ten minutes on a smokescreen while the thing that would have killed the deal stays in their pocket.
4. Go back to the people you already paid to meet
Most salespeople call a lead dead after two or three follow-ups. A lot of those people never said no. They got busy. They got scared. Another fire started at work and your email went under it.
That list is not trash. It is pipeline you already spent time and money to create.
Send something almost too direct.
Have you given up on [the problem]?
Then a short note. You have not heard from them. You want to know if this is still a priority. If they have moved on, you will stop writing and take them off the list. If they have not, they can just say so.
That email does two jobs at once. It clears the people who were never going to buy, which is a gift to your week. And it wakes up the ones who still want the thing but needed a reason to reopen the tab.
Do not re-pitch the company. Do not attach a deck. One question, one kind way out, one easy yes. The politeness of “just circling back” is why those emails die in the same pile as everyone else’s.
5. Speed beats looking busy
This is not dating. You do not get extra credit for waiting two days so you seem in demand.
If a lead comes in at 10:00 on a Monday, follow up at 10:01. Tell them the truth. An email just landed, you saw they were interested, you wanted to get them what they asked for while it was still warm.
People remember the person who moved. They also hire the person who moved, more often than they admit.
The other half of this is a rhythm you can see. You cannot hunt hard for three weeks, vanish for a quarter, then act surprised when nothing is closing. Pick a weekly shape and keep it, even when it feels boring. Your version might be fifty conversations in, ten meetings booked, six presentations, two closes. The numbers will be different for your offer. The point is you can look at the week on a page and know if the machine ran.
When the numbers slip, you will know where. Too few conversations. Meetings that do not show. Presentations that never get a next step. That is a lot more useful than a vague sense that “sales feels slow.”
Confidence does not show up first and then you start doing the work. It shows up because you did the same simple things on a Tuesday when you did not feel like it.
Build that, and the business stops depending on whether you woke up brave.
Daniel Priestly inspired the sales points I shared with you and he breaks down 10 powerful sales tips to increase your sales:

The post 5 Sales Moves That Quietly Fill a Startup Pipeline appeared first on Addicted 2 Success.

Lindell lost to Minnesota House Speaker Lisa Demuth in the Minnesota GOP gubernatorial primary.

A new Wall Street study just put real numbers behind something workers have suspected for years. Artificial intelligence isn’t just changing how people work; it’s also changing who gets hired.

Goldman Sachs spent months tracking the data across multiple countries, and the picture that emerged is more specific and useful than the usual AI doom headlines.

Goldman Sachs AI jobs report: entry-level workers and call-center employment 2026

Artificial intelligence has started to weigh on the labor markets across major developed economies, but effects vary by industry and level. Goldman found that industries with greater AI exposure have generally seen slower job openings growth since the second half of 2022, a pattern especially pronounced in the United States.

Information and communication services, among the most AI-exposed industries, have seen slowing employment growth across nearly every major developed economy since 2022, according to BeInCrypto, Goldman said in the report published Aug. 19.

Outside the U.S., though, employment in those industries still sits near or above its long-term trend.

More Goldman Sachs:

Goldman Sachs sees writing on the wall for Eli Lilly stock

Goldman Sachs doubles down on oil price forecast for 2026

Goldman Sachs gives major reset to YETI Holdings stock target

Call centers stand out as the clearest example. Employment in the industry is now 39% below trend in the U.S., 33% below trend in Canada, and 27% below trend in Germany, Goldman found, alongside similar declines in software publishing, management consulting, and advertising.

The pain isn’t spread evenly by age or experience, either.

Goldman analyzed employment growth across more than 800 occupations and found AI-related headwinds were strongest among entry-level workers, with a smaller but still negative effect on occupations Goldman considers highly exposed to displacement, CNBC reported.

AI job losses of 16,000 per month: what Goldman payroll data show

This isn’t the first time Goldman has flagged the trend. The bank has estimated AI could displace roughly 15 million American workers over the next decade, about 9% of the workforce.

The forecast landed the same month June payrolls came in at just 57,000, less than half of what economists expected, according to TheStreet.

Peng broke the monthly job picture into two columns. The substitution column, where AI replaces a human outright, runs at about 25,000 a month. The augmentation column, where AI creates adjacent work, adds back roughly 9,000.

That leaves a hole of about 16,000 every month. By June, the hole had narrowed to about 11,000. Data-center construction was the reason, not any slowdown in what AI was doing to white-collar work.

Younger workers are absorbing most of that gap. Major employers, including Amazon, Oracle, and Meta, have all made deep cuts this year amid an aggressive AI investment push, adding to the pressure on workers trying to reenter the job market.

Goldman Sachs analyzed employment growth across more than 800 occupations.Angela/Getty Images

AI adoption unfolds amid employment slowdown, Fed rate-cut pressure

The employment slowdown is unfolding as AI adoption keeps climbing.

Goldman combined 11 separate surveys measuring AI adoption and found that major developed economies now sit at adoption rates of roughly 15% to 20%, led by France, the U.S., the Netherlands, and the U.K. Meanwhile, Italy, Japan, and New Zealand trail behind, BigGo Finance noted.

That combination, rising AI adoption alongside softer hiring, is exactly what has the Federal Reserve paying closer attention.

A New York Fed study found AI is more likely to reshape jobs than trigger a sudden spike in unemployment in the near term.

But the bank cautioned that AI could gradually restructure the labor market, wages, and productivity, creating longer-term complications for policymakers trying to balance the Fed’s dual mandate of price stability and maximum employment, according to TheStreet.

Goldman economist Joseph Briggs has framed the stakes directly for markets. “If we see some job losses pulled forward, that sets the stage for potential underperformance relative to our forecast, and that may lead the Federal Reserve to cut rates,” he said.

July payrolls were down 23,000. Unemployment was 4.1%. Those two numbers don’t usually move together.

Payrolls drop when people lose jobs. Unemployment drops when people find them. Something in the middle is happening, and Goldman’s data is one of the better attempts to explain what.

What Goldman Sachs’ AI labor market warning means for workers, job seekers

There are no mass layoffs in Goldman’s data. What there is: a manager whose team of five used to handle a workload that three people can now cover with AI tools.

Two positions just quietly disappeared from next year’s headcount plan. No announcement. No severance. The jobs never came back.

That distinction matters for how the labor market evolves going forward. The reason early AI deployment hasn’t visibly hurt workers more is that the occupations most exposed to AI were already short-staffed, giving the market a built-in cushion.

That cushion is largely gone now, and the next wave of automation is likely to land on occupations that are no longer running short on candidates.

For all the young workers and policymakers, the practical takeaway is to watch the adoption rates and entry-level hiring as leading indicators, and not the unemployment rate.

As Goldman’s own data show, the real pressure builds well before it shows up there.

Related: Bank of America gives surprise verdict on AI, U.S. jobs 

More people under 30 are using gambling as a shortcut to buying a home or paying student loans

It’s not often that a small drug company convinces Wall Street’s big banks that its stock could double.

Nuvation Bio (NUVB) just got that call.

On Tuesday, Aug. 18, 2026, JPMorgan started covering the stock with an Overweight rating, which is the firm’s way of saying it expects the shares to beat the market. 

The bank set a price target of $13, roughly double where the stock recently traded.

A price target is an analyst’s estimate of where a stock could go over a set period, and JPMorgan’s target runs through Dec. 2027. So this is a long-term call, not a quick trade.

The reason for the bank’s optimism is a product that reached the market this year.

Here is what the call means for investors — and where the risks are.

What is behind JPMorgan’s 100% upside call on Nuvation Bio

JPMorgan’s confidence rests mostly on IBTROZI, a lung cancer pill that Nuvation launched earlier in 2026.

The drug treats a specific group of non-small cell lung cancer patients whose tumors carry a change in a gene called ROS1. It works as a targeted therapy, meaning it goes after that specific genetic driver instead of attacking cells broadly the way older chemotherapy does.

Related: UBS strongly resets Lilly stock target

IBTROZI reached the market at a good moment for the company. In the first half of 2026, it became the most prescribed ROS1 targeted therapy for both new patients and first-time treatments, according to Investing.com.

That early lead matters because it shows doctors are choosing the drug quickly, which is the clearest sign a new medicine can grow into steady revenue.

How IBTROZI’s fast start showed up in Nuvation’s earnings

The strong sales are no longer a projection. It appeared in the company’s most recent quarter.

On Aug. 6, 2026, Nuvation reported second-quarter revenue of $31.7 million, ahead of the roughly $27 million analysts expected, according to a press release. Net product sales from IBTROZI made up $23.2 million of that total.

More Healthcare Stocks:

BofA biotech scorecard: Two buys and odd one out

BofA stays bullish on Gilead after a strong HIV signal

J&J’s biotech progress could punish its 2027 profit

The company still lost money, though. Adjusted loss came in at 18 cents a share, three cents worse than expected, as Investing.com noted. That gap between rising sales and continued losses is normal for a young drug company. 

Nuvation is spending heavily to build its sales force and push more drugs through testing, which eats into profit today in exchange for a shot at bigger revenue later.

The revenue side of the story is working faster than expected, even as profits stay negative for now.

The second drug that could widen Nuvation’s opportunity

IBTROZI is not the only reason JPMorgan likes the stock. The bank also pointed to safusidenib, an experimental drug for a type of brain tumor called IDH1-mutant glioma. 

JPMorgan sees strong sales potential if the drug clears its remaining studies.

Safusidenib is still in testing, so it carries no revenue yet. The key data that will show whether it works, called progression-free survival readouts, are still years away.

That timeline is worth remembering. One drug, IBTROZI, is already selling, while the second is years away from proving itself.

A stock with one commercial product and one promising candidate can move sharply in either direction on trial news.

Why the stock looks cheap compared with its own history

Part of JPMorgan’s argument is that Nuvation trades well below its past valuation.

The stock’s price-to-sales ratio, which compares its market value to its yearly revenue, sits near 14.8. 

JPMorgan sees room for the shares to rise if sales keep climbing, since the ratio is still low for a commercial-stage cancer drug maker.

A low price-to-sales figure alone does not make a stock a bargain. It only helps if the company keeps growing revenue, which is exactly the bet here.

Nuvation’s stock has actually fallen about 18% since the start of 2026, closing near $6.48 before JPMorgan’s call. Over the past five trading days, though, the shares gained about 8%.

That mix of a weak year and a recent bounce is the setup JPMorgan is stepping into.

The risks every Nuvation investor should weigh first

The upside case comes with real dangers, and they deserve equal attention.

Small biotech companies that depend on one or two drugs can lose most of their value if sales slow or a trial fails. Nuvation fits that profile.

A few specific risk factors stand out:

Key risks for Nuvation Bio investors

The stock carries a beta of 1.52, meaning it tends to move about 52% more than the overall market, according to MarketBeat.

The stock has traded as high as $9.75 over the past year, showing how wide the swings can be.

The company posts a negative net margin near 88% and a negative return on equity around 47%, so standard profit measures do not yet apply.

Insiders have been net sellers of the stock in recent months, a cautious signal from the people who know the company best.

To fund its spending, Nuvation raised $250 million through a 0.75% convertible notes offering in June 2026.

The amount grew to $287.5 million once underwriters fully exercised the over-allotment option. 

The company also has a pending $30 million milestone payment tied to European IBTROZI approval, expected in the first half of 2027, from partner Eisai.

That cash gives the company room to operate, but it also shows how much money a biotech burns before it turns a profit.

Nuvation Bio’s lung cancer drug IBTROZI is driving the company’s first real sales.SOPA Images / Getty Images

Where the rest of Wall Street stands on Nuvation Bio

JPMorgan is bullish, but it is not standing alone, and it is not the most aggressive voice either.

Nuvation holds a Strong Buy consensus rating. All eight analysts covering the stock rate it a Buy, with an average price target of  $14.86.

That average is above JPMorgan’s call, which means that even among believers, opinions on how far the stock can run vary a great deal.

What Nuvation still needs to prove

A 100% gain is a target, not a promise, and several things must go right first.

IBTROZI needs to keep taking market share, not just win early adopters. 

The company’s next earnings report, expected around Nov. 2, 2026, will show whether the sales momentum held through the third quarter.

Safusidenib needs clean trial data before it can add meaningful revenue, and that answer is years out.

For investors, the practical approach is to treat Nuvation as a higher-risk position rather than a core holding. The reward could be large, but so could the loss if a single drug stumbles.

Watch the November earnings report and the drug’s prescription trends to see whether the target is realizable.

Related: Goldman Sachs sees writing on the wall for Eli Lilly stock